Compare · ABBV vs LFVN
ABBV vs LFVN
Side-by-side comparison of AbbVie Inc. (ABBV) and Lifevantage Corporation (LFVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and LFVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 5748.4x LFVN ($78.2M).
- Over the past year, ABBV is up 34.5% and LFVN is down 52.0% - ABBV leads by 86.5 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 3 for LFVN).
- ABBV has more recent analyst coverage (25 ratings vs 2 for LFVN).
- Company
- AbbVie Inc.
- Lifevantage Corporation
- Price
- $254.52+0.06%
- $6.21+0.32%
- Market cap
- $449.63B
- $78.2M
- 1M return
- +14.38%
- +2.99%
- 1Y return
- +34.48%
- -52.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 23
- 3
- Recent ratings
- 25
- 2
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Lifevantage Corporation
LifeVantage Corporation engages in the identification, research, development, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The company offers Protandim, a line of scientifically-validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, and hand creams, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. The company sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, and China. LifeVantage Corporation is headquartered in Sandy, Utah.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest LFVN
- Chief Financial Officer Aure Carl covered exercise/tax liability with 1,361 shares, decreasing direct ownership by 0.87% to 155,554 units (SEC Form 4)
- Chief Sales Officer Cunningham Kristen covered exercise/tax liability with 1,717 shares, decreasing direct ownership by 1% to 131,417 units (SEC Form 4)
- General Counsel Neufeld Alissa covered exercise/tax liability with 1,342 shares, decreasing direct ownership by 1% to 112,744 units (SEC Form 4)
- Director Lewis Darwin bought $6,059 worth of shares (705 units at $8.60), increasing direct ownership by 0.52% to 137,268 units (SEC Form 4)
- Director Beindorff Michael A sold $85,459 worth of shares (10,000 units at $8.55) (SEC Form 4)
- Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Lifevantage Corporation
- LifeVantage Declares Quarterly Dividend
- LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026
- LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026